

# ACR

# Pediatric Rheumatology SYMPOSIUM MARCH 29-APRIL 1



AMERICAN COLLEGE  
of RHEUMATOLOGY  
*Empowering Rheumatology Professionals*

All times listed in Central Daylight Time (CDT)

Schedule is subject to change

## Wednesday, March 29

6:15–7:15 PM	Opening Reception	Storyville Hall
--------------	-------------------	-----------------

## Thursday, March 30

7:00–8:00 AM	Continental Breakfast		Storyville Hall
8:00–8:15 AM	Welcome and Opening Remarks	<b>Bryce Binstadt, MD, PhD</b> <i>University of Minnesota</i>	Celestin D-E
8:15–9:00 AM	Opening Session–Keynote	<b>Stacy Ardoin, MD, MPH</b> <i>Nationwide Children's Hospital</i>	

### OPENING SESSION–THE BIG PICTURE

9:00–9:30 AM	Collaborative/Translational Research	<b>Eve Smith, MD, PhD</b> <i>University of Liverpool</i>	Celestin D-E
9:30–10:00 AM	Single Cell Omics	<b>Deepak Rao, MD, PhD</b> <i>Brigham and Women's Hospital</i>	
10:00–10:15 AM	Break		Celestin Foyer

### CARDIOVASCULAR EFFECTS IN PEDIATRIC RHEUMATIC DISEASES SESSION

10:15–10:45 AM	Listening for The Silent Killer: Assessment of Subclinical Cardiovascular Disease in Children with Lupus in Practice and Research	<b>Joyce Chang, MD, MSCE</b> <i>Boston Children's Hospital</i>	Celestin D-E
10:45–11:15 AM	Biomarkers for CV Disease Risk Stratification in Children and Adolescents with Lupus	<b>Coziana Ciurtin, FRCP, MD, MSc, PhD</b> <i>University College London</i>	
11:15–11:45 AM	Heart on Fire: Immunobiology of Cardiovascular Inflammation in Rheumatic Disease	<b>Mark Gorelik, MD</b> <i>Columbia University School of Medicine</i>	
12:00–1:00 PM	Lunch <i>(box lunch included)</i>		Storyville Hall
	Roundtable Topic Discussions		Celestin G-H
12:00–1:00 PM	American Board of Pediatrics Maintenance of Certification Session <i>(Optional)</i>	<b>Keith J. Mann, MD, MEd</b> <i>American Board of Pediatrics</i>	Celestin D-E



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

HEALTH DISPARITIES IN PEDIATRIC RHEUMATOLOGY AND STRATEGIES TO MITIGATE THEIR EFFECTS			
1:00–1:30 PM	Update on Disparities in Pediatric Rheumatology	<b>Jennifer Woo, MPH, PhD</b> <i>National Institute of Environmental Health Sciences (NIEHS)</i>	Celestin D-E
1:30–2:00 PM	Suggestions to Mitigate Disparities in Clinical Care	<b>Alisha Akinsete, MD (Virtual)</b> <i>Hospital for Special Surgery</i>	
2:00–2:30 PM	Q&A Panel Discussion	<b>Jennifer Woo, MPH, PhD</b> <b>Alisha Akinsete, MD (Virtual)</b>	
2:30–3:30 PM	<b>Plenary Abstracts Session I</b>		
	<b>#001</b> Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System	<b>Jordan Roberts, MD, MPH</b> <i>Seattle Children's Hospital</i>	Celestin D-E
	<b>#002</b> Re-analysis of the APPLE [Atherosclerosis Prevention in Paediatric Lupus Erythematosus] Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression	<b>Coziana Ciurtin</b> <i>University College London</i>	
	<b>#003</b> Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis	<b>Emily Hause, MD MPH</b> <i>University of Minnesota</i>	
	<b>#004</b> Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression	<b>Camilla Wibrand</b> <i>University of California San Francisco</i>	
3:30–4:00 PM	Break		Celestin Foyer



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

SYSTEMIC LUPUS ERYTHEMATOSUS SESSION			
4:00–4:20 PM	Contemporary Best Practices for Childhood-Onset Lupus	<b>Emily Smitherman, MD, MS</b> <i>University of Alabama at Birmingham</i>	Celestin D-E
4:20–4:40 PM	Genetics in Childhood-Onset Lupus: Monogenic Diseases, Polygenic Models, Risk-Alleles and the Integration of Omics Data	<b>Sarah Baxter, MD, PhD</b> <i>Seattle Children's Hospital and University of Washington</i>	
4:40–5:00 PM	Non-Coding Casual Variants in Systemic Lupus Erythematosus	<b>Peter Nigrovic, MD</b> <i>Boston Children's Hospital</i>	
5:10–5:40 PM <i>(concurrent abstract sessions)</i>	<b>Oral Abstract Poster Breakout 1:</b> Lupus: Genetics, Epigenetics, & Social Determinants		
	<b>#011</b> The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center	<b>Emily F. Beil, MD</b> <i>Baylor College of Medicine, Texas Children's Hospital</i>	Celestin D-E
	<b>#012</b> Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematosus Patients with and Without Severe Hematologic Disturbances	<b>Cathy Tsin, MD</b> <i>Stanford University</i>	
	<b>#013</b> Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus	<b>Laura Lewandowski, MD</b> <i>NIH</i>	
	<b>#014</b> Characterizing Lupus in African American Children in Southern United States	<b>Anita Dhanrajani</b> <i>University of Mississippi Medical Center</i>	
	<b>#015</b> Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus	<b>Joyce Hui-Yuen, MD, MS</b> <i>Cohen Children's Medical Center, Northwell Health</i>	



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

5:10–5:40 PM <i>(concurrent abstract sessions)</i>	<b>Oral Abstract Poster Breakout 2: Juvenile Idiopathic Arthritis &amp; Uveitis: Genetics, Clinical &amp; Therapeutic Aspects</b>		
	<b>#016</b> Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment	<b>Esraa Eloseily, MD</b> <i>Cincinnati Children's Hospital Medical Center</i>	Celestin A
	<b>#017</b> Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study	<b>Ilaria Maccora, MD</b> <i>Cincinnati Children's Hospital</i>	
	<b>#018</b> Using the Electronic Health Record to Identify Subjects with Rheumatic Disease	<b>Alysha Taxter, MD; MS</b> <i>Nationwide Children's Hospital</i>	
	<b>#019</b> Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry	<b>Amieleena Chhabra, MD</b> <i>University of British Columbia</i>	
	<b>#020</b> Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model	<b>Margaret H. Chang, MD; PhD</b> <i>Boston Children's Hospital</i>	



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

Oral Abstract Poster Breakout 3: Pediatric Rheumatology Potpourri			
5:10–5:40 PM <i>(concurrent abstract sessions)</i>	<b>#021</b> Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic	<b>Sara M. Stern, MD</b> <i>University of Utah Department of Pediatrics</i>	Celestin F
	<b>#022</b> Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias	<b>Aviya Lanis</b> <i>Seattle Children’s Hospital</i>	
	<b>#023</b> Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle	<b>Lauren Covert, MD</b> <i>Duke University</i>	
	<b>#024</b> Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging	<b>Hermine I. Brunner, MD; MSc; MBA</b> <i>Cincinnati Children’s Hospital Medical Center</i>	
	<b>#025</b> Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance [CARRA] Registry	<b>Emily A. Smitherman, MD; MS</b> <i>University of Alabama at Birmingham</i>	
6:00–7:00 PM	Abstract Poster Session <i>(Abstracts #41 – #89)</i>	Poster Presenters	Storyville Hall



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

## Friday, March 31

7:00–8:00 AM	Continental Breakfast	Storyville Hall
--------------	-----------------------	-----------------

### JUVENILE IDIOPATHIC ARTHRITIS SESSION

8:00–8:30 AM	Management of Refractory Juvenile Idiopathic Arthritis	<b>Melissa Mannion, MD</b> <i>University of Alabama at Birmingham</i>	Celestin D-E
8:30–9:00 AM	Treatment Withdrawal in Juvenile Idiopathic Arthritis	<b>Joost Swart, MD, PhD</b> <i>Wilhelmina Children's Hospital / UMC Utrecht</i>	
9:00–9:30 AM	Management of Uveitis: Refractory Disease and Treatment Withdrawal	<b>Ashley Cooper, MD</b> <i>Children's Mercy Kansas City</i>	
9:30–10:00 AM	Roundtable/Panel Discussion	<b>Melissa Mannion, MD</b> <b>Joost Swart, MD, PhD</b> <b>Ashley Cooper, MD</b>	
10:00–10:30 AM	Break		Celestin Foyer

### JUVENILE DERMATOMYOSITIS AND SCLERODERMA SESSION

10:30–11:00 AM	Clinical Updates in Juvenile Dermatomyositis Related Calcinosis	<b>Dawn Wahezi, MD, MS, RhMSUS</b> <i>Children's Hospital at Montefiore</i>	Celestin D-E
11:00–11:30 AM	Immune Dysregulation in Juvenile Dermatomyositis	<b>Jessica Neely, MD</b> <i>University of California, San Francisco</i>	
11:30 AM–12:00 PM	An Update On Autoantibodies in Juvenile Myositis	<b>Lisa Rider, MD</b> <i>National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH)</i>	
12:00–12:30 PM	Scleroderma – Single Cell Omics	<b>Kathryn Torok, MD</b> <i>University of Pittsburgh</i>	
12:30–1:30 PM	Lunch ( <i>box lunch included</i> )		Storyville Hall
	Roundtable Topic Discussions		Celestin G-H



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

**TRANSITIONAL AND REPRODUCTIVE CARE CONCURRENT SESSION**

1:30–2:00 PM	Defining & Implementing High-Quality Transitional Care in Pediatric Rheumatology	<b>Patience White, MD</b> <i>Got Transition</i>	Celestin D-E
2:00–2:30 PM	Reproductive Health in Rheumatic Diseases: What a Pediatric Rheumatologist Needs to Know	<b>Bonnie Bermas, MD</b> <i>UT Southwestern Medical Center</i>	

**CLINICAL MANAGEMENT/TREAT TO TARGET CONCURRENT SESSION**

1:30–2:00 PM	Can US Guide Treat to Target?	<b>Johannes Roth, FRCPC, MD, PhD, RhMSUS</b> <i>University of Ottawa</i>	Celestin A
2:00–2:30 PM	Treat to Target	<b>Eve Smith, MD, PhD</b> <i>University of Liverpool</i>	
2:30–3:00 PM	<b>Plenary Abstracts Session II</b>		Celestin D-E
	#005 Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study	<b>Emily Zhang</b> <i>Boston Children's Hospital</i>	
	#006 Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic	<b>Lauren Harper, MD</b> <i>Nationwide Children's Hospital</i>	
3:00–3:15 PM	Break		Celestin Foyer



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

**VASCULITIS CONCURRENT SESSION**

3:15–3:35 PM	cPACNS: Quality of Life and Cognitive Outcomes in Childhood Cerebral Vasculitis	<b>Susa Benseler, FRCPC, MD, PhD</b> <i>University of Calgary, Canada</i>	Celestin D-E
3:35–3:55 PM	Treatment Update for the Vasculitis Missed Most: Takayasu Arteritis	<b>Seza Ozen, MD, MSc</b> <i>Hacettepe University</i>	
3:55–4:15 PM	Advanced Imaging in Takayasu Arteritis	<b>Kaitlin Quinn, MD, MHS</b> <i>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)</i>	

**MENTAL HEALTH IN PEDIATRIC RHEUMATOLOGY CONCURRENT SESSION**

3:15–3:35 PM	Psychoneuroimmunology Concepts and Stress/Mental Health in Pediatric Rheumatology	<b>Ryan Brown, MD</b> <i>University of California, San Francisco</i>	Celestin G-H
3:35–3:55 PM	Resilience in Pediatric Rheumatology	<b>Sabrina Gmuca, MD, MSc</b> <i>Children's Hospital of Philadelphia</i>	
3:55–4:15 PM	Panel Discussion	<b>Ryan Brown, PhD</b> <b>Sabrina Gmuca, MD, MSc</b>	





All times listed in Central Daylight Time (CDT)

Schedule is subject to change

4:30–5:00 PM (Concurrent abstract sessions)	<b>Oral Abstract Poster Breakout 4: Juvenile Dermatomyositis &amp; Scleroderma: Clinical &amp; Therapeutic Aspects</b>		
	<b>#026</b> Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort	<b>Sophie Stefancic</b> <i>University of Pittsburgh</i>	Celestin D-E
	<b>#027</b> Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa	<b>Jessica Perfetto, MD</b> <i>Children's Hospital at Montefiore</i>	
	<b>#028</b> Achieving Medication-Free Remission in Juvenile Dermatomyositis	<b>Sheila T. Angeles-Han, MD; MSc</b> <i>Cincinnati Children's Hospital</i>	
	<b>#029</b> Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience	<b>Meredith Rae, MD</b> <i>Baylor College of Medicine</i>	
	<b>#030</b> International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update	<b>Kevah Ardalan, MD</b> <i>Duke University</i>	



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

4:30–5:00 PM [Concurrent abstract sessions]	<b>Oral Abstract Poster Breakout 5:</b> Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C s		
	<b>#031</b> Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants	<b>Greta Mastrangelo</b> <i>University of Toronto</i>	Celestin A
	<b>#032</b> From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy	<b>Merav Birk-Bachar</b> <i>Schneider Children's Medical Center of Israel</i>	
	<b>#033</b> Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)	<b>Lyndsey Cole, MD</b> <i>University of Colorado School of Medicine</i>	
	<b>#034</b> STAT3 Gain-of-function Syndrome Mutations Are Susceptible to JAK Inhibition Despite a Spectrum of Potency	<b>Herda Ona</b> <i>Baylor College of Medicine</i>	
	<b>#035</b> SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome	<b>Mariana Sanchez Villa, MS</b> <i>Baylor College of Medicine</i>	



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

	<b>Oral Abstract Poster Breakout 6: Systemic Juvenile Idiopathic Arthritis: Genomics, Transcriptomics &amp; Disease States</b>		
4:30–5:00 PM [Concurrent abstract sessions]	<b>#036</b> Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease	<b>Claudia Bracaglia, MD</b> <i>IRCCS Ospedale Pediatrico Bambino Gesù</i>	Celestin F
	<b>#037</b> Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes	<b>Susan Canny, MD; PhD</b> <i>Seattle Children's Hospital</i>	
	<b>#038</b> HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy	<b>Claudia Bracaglia, MD</b> <i>IRCCS Ospedale Pediatrico Bambino Gesù</i>	
	<b>#039</b> Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score	<b>Silvia Rosina, MD; PhD</b> <i>IRCCS Istituto Giannina Gaslini</i>	
	<b>#040</b> HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis	<b>Alison Lerman, MD</b> <i>University of Minnesota</i>	
5:00–6:00 PM	Abstract Poster Session <i>(Abstracts #90 – #137)</i>	<i>Poster Presenters</i>	Storyville Hall
6:30–8:00 PM	Awards Dinner		Celestin D-E



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

## Saturday, April 1

7:00–8:30 AM	Continental Breakfast	Storyville Hall
--------------	-----------------------	-----------------

### VIRUSES AND AUTOIMMUNITY CONCURRENT SESSION

8:30–9:00 AM	Mechanisms of Virus-Induced Autoimmunity	<b>Marc Horwitz, MD</b> <i>University of British Columbia</i>	Celestin D-E
9:00–9:30 AM	Anti-IFN Antibodies in Severe COVID-19	<b>Helen Su, MD, PhD</b> <i>National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)</i>	
9:30–10:00 AM	Autoantibodies in COVID-19	<b>Paul Utz, MD</b> <i>Stanford University</i>	

### PRECISION THERAPEUTICS CONCURRENT SESSION

8:30–9:00 AM	HLA-Associated Drug Response	<b>Ruud Verstegen, MD, PhD</b> <i>The Hospital for Sick Children</i>	Celestin F
9:00–9:30 AM	Precision Therapeutics: Describe the Principles of Pharmacogenetic Testing and the Clinical Guidelines Currently Available	<b>Stephen Balevic, MD, PhD, RhMSUS</b> <i>(Virtual) Duke University</i>	
9:30–10:00 AM	Therapeutic Drug Monitoring in Pediatric Rheumatology: Time for Tailored Therapy?	<b>Carmela Sagcal-Gironnella, MD, MS</b> <i>Hackensack University Medical Center</i>	
10:00–10:30 AM	Break		Celestin Foyer

### NOVEL TREATMENTS SESSION

10:30–11:00 AM	Allogeneic Bone Marrow Transplant for Refractory Rheumatic Diseases	<b>Rebecca Marsh, MD</b> <i>Cincinnati Children's Hospital Medical Center</i>	Celestin G-H
----------------	---	--	--------------



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

11:00 AM–12:00 PM	<b>Plenary Abstracts Session III</b>		
	<b>#007</b> Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis	<b>Kathryn Torok, MD</b> <i>University of Pittsburgh</i>	Celestin D-E
	<b>#008</b> Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis	<b>Belina Y. Yi, DO</b> <i>Children's Hospital Los Angeles</i>	
	<b>#009</b> The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease [BACC YARD] Program, a Pediatric-to-Adult Rheumatology Transition Program	<b>John Bridges, MD</b> <i>University of Alabama at Birmingham/Children's of Alabama</i>	
<b>#010</b> Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus: A Preliminary Investigation	<b>Doborah Levy, MD</b> <i>The Hospital for Sick Children</i>		
12:15–1:15 PM	Lunch <i>(box lunch included)</i>		Storyville Hall
	Roundtable Topic Discussions		Celestin G-H

**TELEHEALTH CONCURRENT SESSION**

1:15–1:35 PM	Telemedicine and Virtual Health: Future Use	<b>Rajdeep Pooni, MD</b> <i>Stanford School of Medicine</i>	Celestin F
1:35–1:55 PM	Using Technology to Engage Patients in Research	<b>Jon Hausmann, MD</b> <i>[Virtual]</i> <i>Beth Israel Deaconess Medical Center</i>	
1:55–2:15 PM	Artificial Intelligence/Machine Learning	<b>Mei Sing Ong, PhD</b> <i>Harvard Medical School &amp; Harvard Pilgrim Health-care Institute</i>	



All times listed in Central Daylight Time (CDT)

Schedule is subject to change

### QUALITY IMPROVEMENT/PATIENT-REPORTED OUTCOMES CONCURRENT SESSION

1:15-1:35 PM	Utilizing PROMIS Measures in Juvenile Dermatomyositis	<b>Kaveh Ardalan, MD, MS</b> <i>Duke University Medical Center</i>	Celestin D-E
1:35-1:55 PM	Patient-Reported Outcomes: Patient Care and Research	<b>Aimee Hersh, MD</b> <i>University of Utah School of Medicine</i>	
1:55-2:15 PM	Utilization of Patient-Reported Outcomes in Quality Improvement Research	<b>Jon Michael Burnham, MD, MS</b> <i>Children's Hospital of Philadelphia</i>	
2:15-2:30 PM	Break		Celestin Foyer

### SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SESSION

2:30-3:00 PM	Early Introduction of Biologics in Systemic Juvenile Idiopathic Arthritis: Its Impact on Disease Course and Long-Term Outcome	<b>Sebastiaan Vastert, MD, PhD</b> <i>University Medical Center Utrecht</i>	Celestin D-E
3:00-3:30 PM	Lung Disease in Systemic Juvenile Idiopathic Arthritis	<b>Alexei Grom, MD</b> <i>Cincinnati Children's Hospital Medical Center</i>	
3:30-4:00 PM	Systemic Juvenile Idiopathic Arthritis and Lung Disease: An Update	<b>Elizabeth Mellins, MD</b> <i>(Virtual) Stanford University</i>	

03/23/23